Quick Answer
Cabaletta Bio, Inc. reported Cash and Equivalents of $82.98 million for fiscal year 2025.
Cabaletta Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $82.98M | -49.4% |
| 2024 | $163.96M | -15.2% |
| 2023 | $193.24M | +136.8% |
| 2022 | $81.61M | -33.2% |
| 2021 | $122.22M | +20.5% |
| 2020 | $101.43M | -25.5% |
| 2019 | $136.20M | +312.5% |
| 2018 | $33.02M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $60.21M | -64.7% | -58.7% |
| June 30, 2025 | $145.61M | -18.5% | +10.5% |
| March 31, 2025 | $131.83M | -24.8% | -19.6% |
| December 31, 2024 | $163.96M | -15.2% | -3.9% |
| September 30, 2024 | $170.61M | +47.7% | -4.5% |
| June 30, 2024 | $178.61M | +39.5% | +1.9% |
| March 31, 2024 | $175.29M | +86.8% | -9.3% |
| December 31, 2023 | $193.24M | +136.8% | +67.3% |
- Cabaletta Bio, Inc. showed a decrease of -49.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Cabaletta Bio, Inc.’s cash and equivalents has grown by 151.3% (from $33.02 million to $82.98 million).
- The most recent figure is from Cabaletta Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: